FIELD: biotechnology.
SUBSTANCE: invention relates to a method for detecting a malignant cell in a sample, comprising determining expression levels of 5-HTR1A and/or 5-HTR1B, and can be used in medicine.
EFFECT: determining the expression levels of 5-HTR1A and/or 5-HTR1B can be used for diagnosing the hematological malignancy, determining a prediction, monitoring the effect of the therapy or developing a personalized therapy.
11 cl, 17 dwg, 1 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RARA AGONISTS FOR THE TREATMENT OF AML AND MDS | 2017 |
|
RU2799789C2 |
| COMPOSITIONS AND METHODS FOR BOOSTING THE EFFECTIVENESS OF ADOPTIVE CELL IMMUNOTHERAPY | 2015 |
|
RU2716716C2 |
| PREDICTION OF RESPONSE TO ALVICIDIB BY ANALYSIS OF MITOCHONDRION PROFILE | 2016 |
|
RU2717829C2 |
| USE OF TRI-SUBSTITUTED GLYCEROL COMPOUNDS FOR TREATING HEMATOLOGICAL MALIGNANT TUMOURS | 2007 |
|
RU2474427C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| METHODS OF TREATING USING ANTI-CD123 IMMUNOCONJUGATES | 2019 |
|
RU2816847C2 |
| METHODS FOR PERSONALIZED MEDICAL TESTING EX VIVO FOR HEMATOLOGICAL NEOPLASMS | 2010 |
|
RU2636614C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
